Innovating Works

BER

Desconocido
BETA3_LVH: A multi center randomized placebo controlled trial of mirabegron a new beta3 adrenergic receptor a... AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII participó en un H2020: H2020-PHC-2014-2015 Patients with cardiovascular risk factors, e.g. hypertension and obesity are at risk of developing heart failure with preserved ejection fra...
2015-04-15 - 2022-08-31 | Financiado
NEPHSTROM: Novel Stromal Cell Therapy for Diabetic Kidney Disease AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII participó en un H2020: H2020-PHC-2014-2015 Type 2 diabetes will affect >500 million adults by 2040 and its secondary complications will generate enormous socioeconomic costs - in part...
2015-04-08 - 2021-10-31 | Financiado
PRESTIGE: PREvention of Late Stent Thrombosis by an Interdisciplinary Global European effort AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII participó en un FP7: According to the European Society of Cardiology there has been an increase in the life expectancy at the age of 65 of the European populatio...
Financiado
ARCH: Patient specific image based computational modelling for nimprovement of short and long term outco... AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII participó en un FP7: More than half a million people live in Europe on chronic renal replacement therapy by hemodialysis (HD). This number increases annually at...
Financiado
STELLAR: Stem cell based therapy for kidney repair AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII participó en un FP7: Chronic kidney disease (CKD) affects 8% of the European population and ultimately results in renal failure due to progressive fibrosis. CDK...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.